ERNA · Ernexa Therapeutics Inc
United States · RS rating 2 · As of 2026-10-14
| Price | 2.11 USD |
|---|---|
| 1-day change | -4.5% |
| RS rating (overall / 1M / 3M / 12M) | 2 / 3 / 2 / 3 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 4 / 43 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +51.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +95.5% |
| Market cap (USD) | $5.6M |